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S. Khan,1 M. Cleanthis,2 J. Smout,1 M. Flather3 and G. Stansby1*1Northern Vascular Unit, Freeman Hospital, Newcastle upon Tyne, 2Department of Vascular Surgery, Queen
Elizabeth II Hospital, Gateshead, and 3Clinical Trials Unit, Royal Brompton Hospital, London, UKObjective. To review the published evidence supporting the use of life-style modification in peripheral arterial disease
(PAD).
Design. A systematic search of the medical literature was performed for relevant studies.
Materials. The publications obtained were then searched for randomised clinical trials which reported end-points of
mortality or major cardiovascular event rates with various life-style modifications.
Results. Only one randomised controlled trial was found reporting relevant end-points. Other trials were of other end-
points such as walking distance or biochemical markers.
Conclusions. There is a lack of randomised controlled data proving the benefit of life-style modification in improving
mortality and reducing cardiovascular events in patients with PAD. Despite this there is sufficient evidence to recommend
some life-style modification as part of the overall approach to risk reduction in these patients. There is compelling evidence to
support smoking cessation, increased exercise and improved diet.Keywords: Peripheral arterial disease; Exercise; Diet; Obesity; Weight loss; Smoking.Introduction
It is widely appreciated that modification of risk factor
profile can help to reduce the disease burden of
atherosclerosis and its complications. Since, individ-
uals with PAD are at markedly increased risk of
cardiovascular ischaemic events, early identification of
this population and more effective interventions could
potentially improve both morbidity and survival.
Despite the proven benefits of pharmacological risk
factor modification such as antiplatelet therapy and
treatment of hypertension and hyperlipidaemia, PAD
patients appear to be less intensively treated than
patients with coronary or cerebrovascular disease.1,2
There is good data to suggest that all patients with
PAD should be considered for antiplatelet and lipid
lowering therapy as well as having active treatment of
hypertension and diabetes.3–6 As well as drug therapy,ing author. Professor G. Stansby, Professor of Vascular
hern Vascular Unit, FreemanHospital, Newcastle upon
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: gerard.stansby@nuth.northy.nhs.uk
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disease are usually advised to undergo so-called ‘life-
style change’ as part of secondary prevention. This
usually refers to giving up smoking, increased
exercise, and improved diet and weight loss. These
interventions are clearly harder to study in the context
of randomised trials than are drug therapies, yet if
they are to be funded by governmental or medical
insurance sources evidence will inevitably be required
as to their effectiveness. The current review aims to
summarise the evidence for ‘life-style’ modification in
patients with PAD in order to reduce cardiovascular
risk and suggests clinically based strategies to achieve
this.Methods
Searches were carried out of Medline (1966–January
2004) and Embase (1974–January 2004) using the
subject headings ‘peripheral vascular diseases’
and ‘intermittent claudication’ and keywords ‘diet’,
‘smoking’, ‘weight’ and ‘exercise’. The publicationsEur J Vasc Endovasc Surg 29, 2–9 (2005)
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randomised clinical trials. This yielded a total of 253
publications. The majority of these concerned exercise
therapy (175/253). The abstracts were then read to see
if these dealt with the issue of individual or combi-
nations of life-style modifications and effects on
mortality or cardiovascular event rates. When this
was not clear from the abstract the full paper was
obtained. Only one of the publications reported the
end-points of mortality or cardiovascular event rates
and so a formal systematic review using these end-
points could not be performed.7 We have, therefore,
attempted to review the evidence that exists from the
non-randomised sources identified and expert
opinion.Smoking cessation and PAD
Smoking is undoubtedly related to development of
atherosclerosis in some direct or indirect manner and
is in fact the strongest risk factor for the development
of claudication.8–10 The diagnosis of PAD is made up
to a decade earlier in smokers than in non-smokers10,11
and the severity of PAD tends to increase with the
number of cigarettes smoked.10,12–18 In addition, it is
also a risk factor for asymptomatic PAD found on
population screening.19 Cronenwett et al. found that
patients with IC who had smoked at least 40 pack-
years required reconstructive vascular surgery over
three times more frequently than those who had
smoked less.20 A major amputation rate of 6–11% has
been reported in patients with IC who smoke
compared with no major amputations in non-smo-
kers.21–23 The 5-year mortality rate for patients with IC
who continue to smoke is 40–50%.23–25 In addition,
smokers have a higher graft failure rate after bypass
for PAD than do non-smokers.26–28 Complete and
permanent smoking cessation is by far the most
clinically and cost effective intervention in patients
with atherosclerosis.29 Smoking cessation has been
associated with a rapid decline in the incidence of IC
and the risk of IC for ex-smokers 1 year after quitting is
approximately the same as that for non-smokers.16,17
Patients who stop smoking have a twofold increase in
their 5-year survival rate compared with those who
continue to smoke.30
Simple advice is usually not very effective since
smoking is a form of addiction.29,31,32 One of the first
issues in PAD patients will be to convince the patient
that their disease is related to smoking as this is not
something that is widely appreciated by the general
public. Bloom et al. found that in a survey of PAD
patients only 44% considered PAD to be smokingrelated and almost none thought gangrene and loss of
the leg was smoking related.33 Smoking cessation can
be enhanced by special programs, though patient
motivation remains the cornerstone.34 Combination of
exercise therapy and smoking cessation may also be
beneficial.35 Adjunctive treatments like nicotine repla-
cement therapy (NRT) and Bupropion (a norepi-
nephrine, serotonin and dopamine neuronal uptake
inhibitor) have been successful in increasing the
likelihood of permanent smoking cessation.36
Although data on the specific use of NRT in PAD is
not available it appears safe to use in patients with
cardiovascular disease.37–41 It is unlikely that a busy
clinician will be able to adequately deal with these
issues alone and access to a smoking cessation clinic or
advisor is extremely helpful.29,34,42One key point to
emphasise to the patient is that ‘cutting down’ or the
use of low tar cigarettes31 is not generally regarded as a
mechanism towards completely giving up.
A recent systematic review of smoking cessation for
the secondary prevention of coronary heart disease
showed that quitting smoking is associated with a
substantial risk reduction (36%) in all cause mor-
tality.43 Since, coronary heart disease is the main cause
of death in PAD, and despite the lack of randomised
trial data concerning mortality and cardiovascular
events, it seems beyond doubt that patients with PAD
should be strongly advised to stop smoking. Areas for
valid trials in the future may include more detailed
studies of how this might be best achieved in PAD
patients.Exercise
The risk of PAD is inversely related to previous levels
of physical activity suggesting a protective effect of
exercise.44 Trials have also clearly demonstrated that
walking capacity is increased by exercise training in
patients with claudication and regular exercise
coupled with risk factor modification, especially
smoking cessation, is the cornerstone of conservative
therapy for intermittent claudication.45–49 Time spent
walking was inversely associated with mortality risk
in one study from Japan, especially in non-smokers.50
Recent meta-analyses have shown the benefit of
exercise training in patients with coronary heart
disease and chronic heart failure.51–53 There have,
however, been no studies showing a clear survival
benefit for claudication patients who exercise. Such
studies would be difficult to perform but would be
helpful. In a prospective study of male smokers, age
50–69, leisure time exercise has been found to be
inversely associated with the risk of developingEur J Vasc Endovasc Surg Vol 29, January 2005
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of exercise to improve walking distance rather than
life-span. Exercise in PAD usually involves treadmill
walkingalthoughothermodalities includingupper limb
exercise and pole-striding have been reported.54,55
Supervised exercise conducted for more than 3months
has shown an increase in treadmill exercise perform-
ance.56–61 A meta-analysis of 21 studies of structured
exercise has shown an average 179% increase in
initial claudication distance and a 122% increase
in absolute walking distance on the treadmill.62 A
recent Cochrane review of 10 studies produced similar
results.63 This benefit may be lost if exercise is stopped
although a recent study indicates that benefit may
continue for at least 6 months.52 In addition, exercise-
induced improvement in walking ability results in
improvement in routine daily activities64–66 and
exercise rehabilitation itself is associated with a
minimal morbidity and mortality.67 Peak exercise
performance and peak oxygen consumption have
been shown to improve with treadmill training as
well as decreased heart rate, ventilation and oxygen
consumption at a given submaximal workload.68,69
There is also a decline in systolic blood pressure,
improved glucose metabolism and enhanced smoking
cessation besides significantly increased pain-freewalk-
ing distance and maximum walking distance.70,71
These changes sustain walking exercise for longer
times before claudication pain limits the activity and
improve cardiovascular fitness. Exercise also has a
positive impact on the quality of life and the functional
status of the claudicant.54,72
Despite the lack of data concerning the effects of
exercise on mortality reduction and prevention of
coronary events there is enough general data to
strongly recommend increased exercise to PAD
patients. However, to do this effectively, specific
programs and facilities need to be made available. In
most countries an exercise program is a standard part
of cardiac rehabilitation. However, PAD patients are
disadvantaged as candidates for exercise therapy
because of their limitation in walking. Ideally specific
exercise programs should be provided for PAD
patients, or at least specific arrangements for patients
who are limited with regard to traditional cardiovas-
cular exercise programs such as those for cardiac
rehabilitation. The focus should be on exercise
prolonging life and not necessarily improving walking
distance.Diet and weight loss
There is some evidence that patients with anyEur J Vasc Endovasc Surg Vol 29, January 2005atherosclerotic disease should be on a low fat diet
and animal products with high fat contents and dairy
products should be avoided. There is also evidence for
the benefit of a ‘Mediterranean’ type diet, rich in fruit,
nuts, vegetables, fish and mono-unsaturated vegetable
oils.73,74 In addition, there is now evidence that
patients with PAD should be on lipid lowering
medication irrespective of their blood cholesterol
levels as part of a secondary prevention program.4
Cholesterol reduction with atorvastatin has also been
shown to improve walking distance.75 However, a
Cochrane review of 27 trials (none in PAD) has shown
only a small overall benefit on cardiovascular events
by dietary fat reduction or modification in patients
with a wide range of vascular and non-vascular
conditions.76 Weight control has also been proposed
to form an essential feature of the overall management
strategy in PAD. Obesity is associated with increased
relative risks for total mortality and cardiovascular
diseases.77 Moreover, body mass index has also been
shown to be directly associated with total cholesterol,
blood pressure, and blood glucose levels.77 Abdominal
fat distribution, but not total body fatness, is associ-
ated with peripheral arterial occlusive disease, inde-
pendently of concurrent cardiovascular risk factors.78
Interestingly, it has been suggested that frequent food
intake (grazing) in smokersmay be advantageous with
regard to the development of symptomatic PAD.79
Weight loss can improve insulin sensitivity and
increase HDL-C.80 It may also improve claudication
distance.81 Every overweight PAD patient should be
given an optimal diet plan and goal for weight loss.
Formal obesity programs or self-help groupsmay be of
value in reaching these goals. Exercise may also be
useful in such a scenario.Specific dietary issues in PAD
Fibre
Fibre interferes with the micellar absorption of dietary
cholesterol. Increased fibre intake is associated with
lower incidence of PAD and a greater mean ABPI in
males.8,82 An inverse association has also been
reported between cereal fibre intake and PAD risk in
men.83 However, there is not currently evidence that a
fruit and vegetable diet protects against PAD though a
modest benefit cannot be excluded.84
Sodium restriction
Sodium restriction has been recommended for hyper-
tensives.85,86 Patients with PAD develop a higher
degree of cardiac hypertrophy than other hypertensive
subjects with the same level of mean arterial pressure.
Life-style Modification 5Sodium intake rather than the mechanical factors
seems to be themajor modulation which influences the
degree of cardiac hypertrophy.87 A daily intake of not
more than 100 mmol (6 g of sodium chloride) is
recommended. Diets high in potassium and fibre
contents may also reduce high blood pressure.88–90
Hyperuricemia is also more pronounced in hyperten-
sives complicated by PAD and is associated with a
worsened functional status of peripheral circulation.91
A higher consumption of meat and meat products is
significantly associated with low mean ABPI.82 How-
ever, most PAD patients in practice will achieve good
blood pressure control by drug therapy rather than
dietary change.
Diabetes
IC is about twice as common amongst diabetic patients
as among non-diabetic patients21 and the association
between diabetes mellitus and the development of
PAD is now well established.10,92–94 Hyperglycaemia,
assessed as HbA(1c), is associated with an increased
risk for PAD.95 Insulin resistance seems to play a key
role.96 These subjects have poorer lower extremity
function than those with PAD alone.97 Moreover,
PAD in patients with diabetes is more aggressive,
with early large vessel involvement coupled with
microangiopathy. Diabetic patients with IC have a 35%
risk of sudden ischaemia and a 21% risk of major
amputation, compared with 19 and 3%, respectively,
in non-diabetic patients.98 Therefore, strict dietary
discipline is necessary for appropriate blood glucose
control to limit the damage on limb function.21 The
United Kingdom Prospective Diabetes Study (UKPDS)
has shown a significant reduction in any diabetes
end point (largely microvascular) following strict
blood glucose control.99 This data seems strong
enough to make good diabetic control a priority in
PAD patients.
Alcohol
Moderate alcohol consumption is associated with a
reduced risk of cardiovascular disease. An inverse
association between alcohol consumption and PAD
has also been reported in the non-smoking popu-
lation.100 However, with increasing consumption there
is a higher risk of hypertension and other cardiac and
non-cardiac diseases resulting in higher morbidity and
premature mortality.101,102 The data is probably not
strong enough to stress consumption of alcohol as part
of the life style approach to PAD.
Antioxidants
Antioxidant capacity is reduced in patients with PAD
and this may in part be determined by the nutritionalstatus.103 Although regular supplementation of vita-
mins is not often recommended routinely, certain
studies have shown some association and perhaps
some clinical benefit. The main substances usually
considered are vitamins E and C. Vitamin E is capable
of preventing oxidation of polyunsaturated fatty
acids and Vitamin C appears capable of preventing
endothelial dysfunction in claudicants.104 The Rot-
terdam study reported a significant inverse effect of
vitamin C intake on prevalence of PAD in the
female population and a similar effect of vitamin E
(alpha-tocopherol) in the male population.105 The
Edinburgh artery study also reports a positive
association of low vitamin E intake in subjects with
low ABPI (PZ0.04) and with low vitamin C intake
in current or ex-smokers.82 However, another study
of exercise found no additional benefit of vitamin
E.54 A large prospective study of male smokers
showed an inverse association of vitamin C intake
and other antioxidants with subsequent risk of
developing IC.8
A Cochrane review of five studies concluded that
there was insufficient evidence to currently rec-
ommend it use in claudication and none of the trials
allowed evaluation of vitamin E treatment on amputa-
tion rate or mortality.106 In addition, the heart
protection study and the heart outcome prevention
evaluation study failed to show any benefit of
antioxidant vitamins in the context of large random-
ised studies.4,107
Homocysteine
Homocysteine is a product of intracellular metabolism
of the amino acid methionine. It circulates in the blood
in oxidised form bound to plasma proteins. Among
the arteriopaths the incidence of hyperhomocysteinae-
mia may be as high as 60% compared with 1% in the
general population108,109 and has been observed as a
stronger risk factor for PAD than coronary artery
disease (CAD).110 These raised levels of homocysteine
can be dealt effectively by addition of folate, pyridox-
ine and vitamin B12. Men with lower folate intake are
at a higher risk of developing PAD.83 There is also a
weak inverse association between the intake of
vitamin B6 and PAD risk. It has also been shown to
be a risk factor for PAD in young women.111 However,
there have been no studies showing the benefit of
lowering homocysteine in PAD and it should probably
only be actively treated in younger patients or those
with particularly high levels.
L-Arginine
L-Arginine is an amino acidwhich is the natural substrate
for nitric oxide formation.112,113 Administration ofEur J Vasc Endovasc Surg Vol 29, January 2005
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imental models of arterial disease.112 It has been
suggested that enteral or parenteral administration of
L-arginine may represent a strategy for preventing
and treating cardiovascular disease clinically.112 In
one study patients with IC were given infusions of
L-arginine and this produced statistically significant
improvements in both pain-free and absolute
walking distance.114 Another study has shown
improvements in walking distance in claudicants
using a food bar enriched with L-arginine.115 After 2
weeks pain fee walking, distance increased 68% in the
treatment group. More data would be needed,
however, before this could be recommended as a
routine therapy.Fish oils
A trial of gamma-linoleic acid and eicosapentanoic
acid in 120 claudicants showed a statistically signifi-
cant benefit in systolic blood pressure but no other
parameters, although there was a trend towards
fewer coronary events after 2 years follow-up.7
Another trial of fish oil supplementation in 32
claudicants showed no benefit in walking distance
but did show a favourable change in blood
lipids.116 A combination of extra-virgin olive oil
and fish oil supplements produced similar
results.117 A recent Cochrane review also concluded
that despite some beneficial effects on haemody-
namic parameters there is no evidence of improved
clinical outcomes.118Conclusions
There is a lack of randomised controlled data proving
the benefit of life-style modification in improving
mortality and reducing cardiovascular events in
patients with PAD. Despite this there is sufficient
evidence to recommend some life-style modification
as part of the overall approach to risk reduction in
these patients. There is compelling evidence to
support smoking cessation, increased exercise and
improved diet. Evidence for individual dietary modi-
fications is less strong. This lack of randomised
controlled data is contrast to that for interventions of
pharmacological interventions such as lipid lowering
and antiplatelet drugs.4,6,119,120 Whilst accepting that
trials may be methodologically difficult, such data will
be important in justifying resources to provide
effective interventions such as smoking cessation
support and exercise classes.Eur J Vasc Endovasc Surg Vol 29, January 2005References
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